Pharmaceuticals

Global Candin Market Expected To Reach $5.78 Billion By 2030 With 6% CAGR

May 5, 2026May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Candin Market Projected To Reach By 2030?

Historical growth was driven by the demand for immune competency assessment, the prevalent use of DTH testing methods, the expansion of hospital diagnostics, the rise in immunosuppressive therapies, and the advancement of clinical immunology.

Anticipated growth during the forecast period is primarily driven by an increasing prevalence of immunodeficiency, the broadening scope of immune monitoring protocols, a rise in diagnostic testing volumes, heightened clinical awareness, and improvements in healthcare infrastructure. Concurrently, key trends expected throughout this period include the expanding adoption of immune function diagnostic tests, wider assessment of cell-mediated immunity, a growing demand for diagnostic skin testing, an intensified focus on detecting immunosuppressive disorders, and the reinforcement of hospital-based diagnostic services.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20011&type=smp

Which Major Drivers Are Influencing The Expansion Of The Candin Market?

The rising occurrence of tuberculosis is projected to stimulate the expansion of the candin market in the future. Tuberculosis (TB), a communicable infectious illness caused by Mycobacterium tuberculosis, primarily targets the lungs but can disseminate to other body parts, spreading via airborne droplets from infected individuals. The increase in tuberculosis incidents stems from various factors, including heightened transmission from unaddressed or undiagnosed cases, the emergence of drug-resistant TB strains, deficiencies in healthcare accessibility, population relocation, and the influence of co-infections such as HIV that compromise immunity. Candin assists in managing tuberculosis by acting as a control in skin tests to assess cell-mediated immunity, differentiating between immune reactions induced by Mycobacterium tuberculosis and non-specific anergic responses in individuals with suspected tuberculosis or weakened immune systems. A pertinent example is that the United States recorded 9,633 tuberculosis cases in 2023, a significant 15.6% increase from the 8,332 cases documented in 2022, as reported by the Centers for Disease Control and Prevention in November 2024. Consequently, the growing prevalence of tuberculosis is propelling the growth of the candin market. The escalating demand for personalized medicine is expected to fuel the growth of the candin market in the foreseeable future. Personalized medicine is a medical strategy that customizes treatment and healthcare services according to unique patient attributes, including genetics, lifestyle, and environmental factors. The proliferation of personalized medicine is being propelled by breakthroughs in genomics, artificial intelligence, and biotechnology, facilitating more precise and effective treatments designed for an individual’s genetic blueprint. Concurrently, the increasing embrace of precision diagnostics and therapies continues to broaden its application across various medical domains. Candin supports personalized medicine by providing diagnostic instruments that allow healthcare providers to customize treatments based on specific patient profiles, such as genetic elements and immune responses, thereby improving treatment effectiveness and reducing adverse reactions. This perfectly aligns with the expanding movement of precision medicine, which depends on targeted therapies and individualized care methodologies. For example, in 2023, the FDA sanctioned 16 novel personalized treatments for patients with rare diseases, an increase from six in 2022, as reported by the Personalised Medicine Coalition in February 2024. Consequently, the rising demand for personalized medicine is a significant driver for the growth of the candin market.

How Is The Candin Market Categorized Across Its Segment Groups?

The candin market covered in this report is segmented –

1) By Indication: Candidiasis, Thrush

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Trends Are Shaping The Candin Market?

A primary trend within the candin market involves concentrating on forming strategic alliances to provide non-invasive, economical, and efficacious treatment solutions. These alliances are cooperative arrangements between multiple entities designed to utilize their combined strengths, assets, or specialized knowledge for achieving shared objectives, frequently entailing joint risks, benefits, and duties in domains like product innovation, market growth, or advancements. An example occurred in May 2023, when Nielsen BioSciences Inc., a pharmaceutical firm from the US, revealed its licensing agreement with Maruho Co. Ltd., a Japanese pharmaceutical company, to commercialize candin in Japan for treating verruca vulgaris. Consequently, this collaboration will see Maruho providing a substantial initial payment to Nielsen and assuming all expenditures linked to the ongoing development and regulatory processes for Candin, which is a diagnostic skin test intended for addressing verruca vulgaris (commonly known as common warts).

Which Firms Are Influencing Competition In The Candin Market?

Major companies operating in the candin market are Nielsen BioSciences Inc.

Get The Full Candin Market Report:

https://www.thebusinessresearchcompany.com/report/candin-global-market-report

Which Region Has The Greatest Market Share In The Candin Market?

North America was the largest region in the candin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Candin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/candin-global-market-report

Browse Through More Reports Similar to the Global Candin Market 2026, By The Business Research Company

Candidiasis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Systemic Aspergillosis And Systemic Candidiasis Market Report 2026

https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

Specialty Yeast Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-yeast-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795